Sun Pharma Advanced Research Company Limited (NSE:SPARC)
Market Cap | 47.41B |
Revenue (ttm) | 645.96M |
Net Income (ttm) | -2.98B |
Shares Out | 324.52M |
EPS (ttm) | -9.20 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 195,028 |
Average Volume | 253,852 |
Open | 145.05 |
Previous Close | 145.05 |
Day's Range | 143.86 - 146.90 |
52-Week Range | 109.30 - 241.00 |
Beta | 0.31 |
RSI | 45.06 |
Earnings Date | Aug 4, 2025 |
About NSE:SPARC
Sun Pharma Advanced Research Company Limited, a clinical-stage biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops products with a therapeutic focus on oncology and immunology. The company is also developing Vodobatinib (SCO-088), a BCR-ABL inhibitor, for the treatment of refractory chronic myelogenous leukemia that is in phase 2 clinical trial; and Vibozilimod (SCD-044), a selective sphingosine-1-phosphate receptor 1 (S1PR1) agonist, for the treatment of psoria... [Read more]
Financial Performance
In 2024, NSE:SPARC's revenue was 717.66 million, a decrease of -5.00% compared to the previous year's 755.45 million. Losses were -3.43 billion, -11.55% less than in 2023.
Financial StatementsNews

Sun Pharma Advanced Research Q1 Results: Net loss narrows to Rs 51.8 crore, Revenue drops 42.6% YoY
Sun Pharma Advanced Research Company (SPARC) reported a consolidated net loss of Rs 51.8 crore for the quarter ended June 30, 2025 (Q1 FY26), significantly narrowing from the loss of Rs 95.9 crore in ...

SPARC shares drop nearly 20% after key drug trial fails
Shares of Sun Pharma Advanced Research Company (SPARC) declined sharply by nearly 20% after the company announced the discontinuation of clinical trials for its experimental drug Vibozilimod (SCD-044)...

SPARC shares fall over 13% in trade today: Details here
Shares of Sun Pharma Advanced Research Company Ltd (SPARC) declined sharply in Wednesday’s trading session, falling over 13% intraday. As of 9:27 AM, the shares were trading 13.32% lower at Rs 169.19....

Stock Market Today: Rajesh Exports, SCI, RHIM, SPARC, and KEC among top 5 gainers on March 20, 2025
The Indian stock market witnessed significant gains on March 20, 2025, with several stocks rallying strongly. Among them, Rajesh Exports, Shipping Corporation of India (SCI), RHI Magnesita (RHIM), Sun...

SPARC signs binding LOI with UCSF and Tiller Therapeutics for pre-clinical oncology asset
Sun Pharma Advanced Research Company has recently informed exchanges that the company signed a binding Letter of Intent (LOI) with the University of California, San Francisco (UCSF) and Tiller Therape...

Sun Pharma Advanced Research Q2 revenue at Rs 12.86 crore; net loss widens to Rs 107.33 crore
Sun Pharma Advanced Research Company Limited (SPARC) has released its unaudited consolidated financial results for the quarter and half-year ended September 30, 2024, reflecting a challenging period w...